Survivin protein expression and hypoxia in advanced cervical carcinoma of patients treated by radiotherapy

Background. Survivin is strongly overexpressed in the vast majority of cancers. Initial investigations suggest a role for Survivin in radiation resistance. In this study, we investigate the effect of Survivin expression on clinical outcome and its relationship to tumor oxygenation parameters, expression of Hif-1 alpha and anemia in patients with advanced cervical cancers treated with radiotherapy. Material and methods. Biopsies of 44 patients with cervical cancers (Stage JIB: n=9; Stage 11113: n=31; Stage IVA: n=4) treated with radiotherapy were assessed by immunochemistry for expression of Survivin. Relation of Survivin to pretreatment tumor oxygenation parameters (HF5, pO(2)), hemoglobin (hb) level, Hif-1 alpha expression and clinical parameters were investigated. Results. Survivin expression was detected in all tumors of the 44 patients. Seven showed a strong expression and 37 have moderate Survivin expression. Patients whose tumors showed moderate Survivin expression had a 5-year overall survival of 66%. However, only one of the seven patients with strong Survivin expression was alive 45 months after treatment. In a Cox regression analysis, Survivin expression was correlated to poor overall survival (p=0.02, RR=3.3). There was no relationship between Survivin expression and pO(2) or HF5, but rather an inverse correlation with hemoglobin level (p=0.04). Furthermore, for six of the seven tumors with a high Survivin expression, Hif-1 alpha was detected. Conclusion. Survivin protein expression is linked with anemia and prognosis in advanced cervical carcinoma of patients treated by radiotherapy. (c) 2006 Elsevier Inc. All rights reserved.